K. T. Adjou, N. Privat, S. Demart, J. P. Deslys, M. Seman et al., MS-8209, an amphotericin B analogue, delays the appearance of spongiosis, astrogliosis and PrPres accumulation in the brain of scrapie-infected hamsters, Journal of Comparative Pathology, vol.122, pp.3-8, 2000.

A. Agguzi, M. Glatzel, F. Montrasio, M. Prinz, and F. L. Heppner, Interventional strategies against prion diseases, Nature Reviews Neuroscience, vol.2, pp.745-749, 2001.

F. Beranger, A. Mange, J. Solassol, and S. Lehmann, Cell culture models of transmissible spongiform encephalopathies, Biochemical and Biophysical Research Communications, vol.289, pp.311-316, 2001.

F. Beranger, A. Mange, and S. Lehmann, Réticulum endoplasmique, protéasome et maladies à prions, Médecine Sciences, vol.19, pp.778-780, 2003.

S. Björkman and L. O. Elisson, Determination of quinacrine (mepacrine) in plasma by high-performance liquid chromatography with fluorimetric detection, Journal of chromatography, vol.420, pp.341-348, 1987.

S. Björkman, L. O. Elisson, and J. Gabrielsson, Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man, Journal of Pharmacy and Pharmacology, vol.41, pp.160-163, 1989.

B. Caughey and G. S. Baron, Factors affecting interactions between prion protein isoforms, Biochemical Society Transactions, vol.30, pp.565-569, 2002.

B. Caughey and R. E. Race, Potent inhibition of scrapieassociated PrP accumulation by congo red, Journal of Neurochemistry, vol.59, pp.768-771, 1992.

B. Caughey and G. J. Raymond, Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells, Journal of Virology, vol.67, pp.643-650, 1993.

W. S. Caughey, L. D. Raymond, M. Horiuchi, and B. Caughey, Inhibition of protease-resistant prion protein formation by porphyrins and phthalocyanines, Proceedings of the National Academy of Sciences of the USA, vol.95, pp.12117-12122, 1998.

J. Chabry, B. Caughey, and B. Chesebro, Specific inhibition of in vitro formation of protease-resistant prion protein by synthetic peptides, Journal of Biological Chemistry, vol.273, pp.13203-13207, 1998.

S. J. Collins, V. Lewis, M. Brazier, A. F. Hill, A. Fletcher et al., Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model, Annals of Neurology, vol.52, pp.503-506, 2002.

D. Lange, E. C. Danhof, and M. , Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain, Clinical Pharmacokinetics, vol.41, pp.691-703, 2002.

H. Diringer and B. Ehlers, Chemoprophylaxis of scrapie in mice, Journal of General Virology, vol.72, pp.457-460, 1991.

K. Doh-ura, T. Iwaki, and B. Caughey, Lysosomotropic agents and cysteine protease inhibitors inhibit scrapieassociated prion protein accumulation, Journal of Virology, vol.74, pp.4894-4897, 2000.

C. Farquhar, A. Dickinson, and M. Bruce, Prophylactic potential of pentosan polysulfate in transmissible spongiform encephalopathies, Lancet, vol.353, p.117, 1999.

P. Follette, New perspectives for prion therapeutics meeting. Prion disease treatment's early promise unravels, Science, vol.299, pp.191-192, 2003.

S. Frantz, Why are clinical costs so high?, Nature Reviews. Drug Discovery, vol.2, pp.851-852, 2003.

H. Furukawa, M. Takahashi, M. Nakajima, and T. Yamada, Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine, Nippon Rinsho, vol.60, pp.1649-1657, 2002.

L. S. Goodman and A. Gilman, The Pharmacological Basis of Therapeutics, pp.1167-1173, 1960.

T. Kenakin, A Pharmacologic Analysis of Drug-Receptor Interaction, vol.491, 1997.

C. Korth, B. C. May, F. E. Cohen, and S. B. Prusiner, Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease, Proceedings of the National Academy of Sciences of the USA, vol.98, pp.9836-9841, 2001.

T. Koster, K. Singh, M. Zimmermann, and E. Gruys, Emerging therapeutic agents for transmissible spongiform encephalopathies: a review, Journal of Veterinary Pharmacology and Therapeutics, vol.26, pp.315-326, 2003.

S. Lehmann and D. A. Harris, A mutant prion protein displays an aberrant membrane association when expressed in cultured cells, Journal of Biological Chemistry, vol.270, pp.24589-24597, 1995.

N. A. Mabbott, M. E. Bruce, M. Botto, M. J. Walport, and M. B. Pepys, Temporary depletion of complement component C3 or genetic deficiency of C1q significantly delays onset of scrapie, Nature Medicine, vol.7, pp.485-487, 2001.

A. Mange, N. Nishida, O. Milhavet, H. E. Mcmahon, D. Casanova et al., Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures, Journal of Virology, vol.74, pp.3135-3140, 2000.

M. Marella, S. Lehmann, J. Grassi, and J. Chabry, Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release, Journal of Biology Chemistry, vol.277, pp.25457-25464, 2002.

F. Montrasio, R. Frigg, M. Glatzel, M. A. Klein, F. Mackay et al., Impaired prion replication in spleens of mice lacking functional follicular dendritic cells, Science, vol.288, pp.1257-1259, 2000.

D. Peretz, R. A. Williamson, K. Kaneko, J. Vergara, E. Leclerc et al., Antibodies inhibit prion propagation and clear cell cultures of prion infectivity, Nature, vol.412, pp.739-743, 2001.

V. Perrier, A. C. Wallace, K. Kaneko, J. Safar, S. B. Prusiner et al., Mimicking dominant negative inhibition of prion replication through structure-based drug design, Proceedings of the National Academy of Sciences of the USA, vol.97, pp.6073-6078, 2000.

M. Pocchiari, P. Casaccia, and A. Ladogana, , 1989.

B. Amphotericin, A novel class of antiscrapie drugs, Journal of Infectious Diseases, vol.160, pp.795-802

S. A. Priola, B. Caughey, and W. S. Caughey, Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies, Current Opinion in Microbiology, vol.2, pp.563-566, 1999.

S. A. Priola, A. Raines, and W. S. Caughey, Porphyrin and phthalocyanine antiscrapie compounds, Science, vol.287, pp.1503-1506, 2000.

, Rapport préliminaire sur l'utilisation de la mépacrine chez 20 patients ayant un diagnostic de maladie de Creutzfeldt Jakob cliniquement probable, vol.10, 2002.

H. Rudyk, S. Vasiljevic, R. M. Hennion, C. R. Birkett, J. Hope et al., Screening congo red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells, Journal of General Virology, vol.81, pp.1155-1164, 2000.

J. A. Shannon, D. P. Earle, B. B. Brodie, J. V. Taggart, and R. W. Berliner, The pharmacological basis for the rational use of atabrine in the treatment of malaria, Journal of Pharmacology and Experimental Therapeutics, vol.81, pp.307-330, 1944.

S. L. Shyng, M. T. Huber, and D. A. Harris, A prion protein cycles between the cell surface and an endocytic compartment in cultured neuroblastoma cells, Journal of Biology Chemistry, vol.268, pp.15922-15928, 1993.

C. Soto, R. J. Kascsak, G. P. Saborio, P. Aucouturier, T. Wisniewski et al.,

J. Ironside, F. Tagliavini, R. I. Carp, and B. Frangione, Reversion of prion protein conformational changes by synthetic b-sheet breaker peptides, Lancet, vol.355, pp.192-197, 2000.

S. Supattapone, H. B. Nguyen, F. E. Cohen, and S. B. Prusiner,

M. R. Scott, Elimination of prions by branched polyamines and implications for therapeutics, Proceedings of the National Academy of Sciences of the USA, vol.96, pp.14529-14534, 1999.

S. Supattapone, H. Wille, L. Uyechi, J. Safar, P. Tremblay et al., Branched polyamines cure prion-infected neuroblastoma cells, Journal of Virology, vol.75, pp.3453-3461, 2001.

S. Supattapone, K. Nishina, and J. R. Rees, Pharmacological approaches to prion research, Biochemical Pharmacology, vol.63, pp.1383-1388, 2002.

F. Tagliavini, R. A. Mcarthur, B. Canciani, G. Giaccone, M. Porro et al., Effectiveness of anthracycline against experimental prion disease in Syrian hamsters, Science, vol.276, pp.1119-1122, 1997.

F. Tagliavini, G. Forloni, L. Colombo, G. Rossi, L. Girola et al., Tetracycline affects abnormal properties of synthetic PrP peptides and PrPSc in vitro, Journal of Molecular Biology, vol.300, pp.1309-1322, 2000.

A. R. White, P. Enever, M. Tayebi, R. Mushens, J. Linehan et al., Monoclonal antibodies inhibit prion replication and delay the development of prion disease, Nature, vol.422, pp.80-83, 2003.